Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
The affinity dissociation constant (KD) of ADA is an important attribute which can represent the kinetics of antibody development and has rarely been included in immunogenicity assessments of biotherapeutics. European Medicines Agency (EMA) guidance states affinity characterization of ADA response may be required on a case-by-case basis, and assays used for these measurements should be qualified for their intended purpose. Challenges to affinity determination in clinical ADA samples include a combination of assay sensitivity due to the relatively low concentrations of ADA, matrix interference from serum proteins, residual drug, and the polyclonal nature of the ADA response.